Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its "market perform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $484.00 price target on the stock.
Regeneron Pharmaceuticals, Inc. (REGN)
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.regeneron.com
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
REGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
REGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
News
- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target raised by analysts at TD Cowen from $1,020.00 to $1,030.00. They now have a "buy" rating on the stock.MarketBeat
- Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO [Yahoo! Finance]Yahoo! Finance
- Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCOGlobeNewswire
- Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT) [Yahoo! Finance]Yahoo! Finance
- Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)GlobeNewswire
REGN
Earnings
- 2/2/24 - Beat
REGN
Sec Filings
- 4/3/24 - Form 4
- 4/3/24 - Form 4
- 4/1/24 - Form 144
- REGN's page on the SEC website